| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Date of Report (Date of Earliest Event Reported): November 16, 2026 |
| 13 Nov 2026 |
Form 4: Cook Meredith, SR. VP, GENERAL COUNSEL & SEC.
Sold 500 shares ($35.4K) |
| 05 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CREDIT AGREEMENT, dated as of November 4, 2026, by and among ANI PHARMACEUTICALS, Inc., a Delaware corporation (the “Lead Borrower”), the Additional Subsidiary Borrowers (as hereinafter defined), the Guarantors (as hereinafter defined), ... |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
PRINCETON, N.J., November 5, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026. |
| 30 Oct 2026 |
Form 4: Carey Stephen P., SVP & CFO
Sold 2,850 shares ($208K) |
| 29 Oct 2026 | 144 |
| 16 Oct 2026 |
Form 4: Lalwani Nikhil, Director
Sold 5,400 shares ($388K) |
| 15 Oct 2026 | 144 |
| 13 Oct 2026 |
Form 4: Cook Meredith, SR. VP, GENERAL COUNSEL & SEC.
Sold 500 shares ($36.8K) |
| 30 Sep 2026 |
Form 4: Carey Stephen P., SVP & CFO
Sold 2,850 shares ($208K) |
| 16 Sep 2026 |
Form 4: Lalwani Nikhil, Director
Sold 5,400 shares ($383K) |
| 15 Sep 2026 | 144 |
| 14 Sep 2026 |
Form 4: Thoma Jeanne, Director
Sold 1,000 shares ($71.5K) |
| 14 Sep 2026 |
Form 4: Cook Meredith, SR. VP, GENERAL COUNSEL & SEC.
Sold 500 shares ($35.4K) |
| 11 Sep 2026 | 144 |
| 01 Sep 2026 |
Form 4: Carey Stephen P., SVP & CFO
Sold 2,850 shares ($207K) |
| 27 Aug 2026 |
Form 4: Gosebruch Henry O, Director
Received 6,662 shares as a grant or award |
| 27 Aug 2026 |
Form 3: Gosebruch Henry O, Director
No securities owned |
Loading...